5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Cipla Ltd.

•
cipla.comBSE: 500087NSE: CIPLA
Market Cap₹ 1,10,273 Cr.
Current Price
High / Low₹ 1,673 / 1,166
Stock P/E32.7
Book Value₹ 435
Price to Book2.87
Dividend Yield0.95 %
ROCE16.0 %
ROE11.8 %
Face Value₹ 2

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2025 • Pharmaceuticals: 95.3% • New Ventures: 4.7%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 20.8%
  • Company has consistently been profitable over the last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 0.98x)
  • Company comfortably covers its interest (97.0x coverage)
  • Company has a consistent dividend-paying track record

CONS

  • Recent results are weak - TTM profit is down 33.0% versus prior year
  • Total debt has risen sharply - up 180.1% year on year
  • Recurring exceptional / one-off items are inflating headline profit
  • Expensive relative to growth - PEG of 3.0

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY 50NIFTY PHARMANIFTYLARGEMIDCAP250NIFTY100 LOWVOL30NIFTY100 EQL WGT
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
6,2696,5896,5066,0826,6256,9616,9626,5986,8377,4476,9636,4647,119
4,8354,9444,8564,8474,9785,1655,0845,1925,1795,6955,8195,5446,248
Operating Profit1,4341,6451,6491,2351,6471,7961,8781,4061,6581,7531,144920871
OPM %22.88%24.96%25.35%20.30%24.86%25.80%26.97%21.30%24.25%23.53%16.42%14.23%12.23%
136176-10249160191222289259269-70148211
Interest16263018181515141413141317
Depreciation239290233288247272280309253297278425304
Profit before Tax1,3751,5941,4741,2591,6111,7891,9161,5041,7701,8548937071,080
Tax %27.50%27.50%27.50%25.80%27.00%27.00%17.35%18.57%27.00%27.00%24.47%22.20%27.29%
Net Profit9981,155001,1751,3051,5751,2141,2921,353674543786
12.3414.0113.0811.6314.5816.1319.4515.1316.0716.738.376.879.77

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
14,39415,15616,36217,13219,16021,76322,75325,77427,54828,16327,994
11,91812,32913,26513,95114,91117,25117,76319,48320,42522,28023,307
Operating Profit2,4762,8263,0973,1814,2494,5124,9906,2917,1235,8834,687
OPM %17.20%18.65%18.93%18.57%22.18%20.73%21.93%24.41%25.86%20.89%16.74%
229280477369270140330552867606558
Interest15911416819716110611090625457
Depreciation1,3231,3231,3261,1751,0681,0521,1721,0511,1071,2111,305
Profit before Tax1,2221,6692,0792,1783,2903,4934,0385,7026,8215,2244,534
Tax %14.71%14.98%27.39%28.98%27.01%26.73%29.79%27.12%22.43%25.92%25.82%
Net Profit1,0421,4191,5101,5472,4012,5592,8354,1555,2913,8703,363
EPS12.5017.5018.9319.1629.7931.1734.6951.0565.2948.02—
Dividend Payout %15.99%17.12%15.82%20.85%16.77%16.03%24.49%25.47%24.51%27.07%—

COMPOUNDED SALES GROWTH

10 Years:
8%
5 Years:
8%
3 Years:
7%

COMPOUNDED PROFIT GROWTH

10 Years:
11%
5 Years:
10%
3 Years:
11%

STOCK PRICE CAGR

10 Years:
9%
5 Years:
8%
3 Years:
3%
1 Year:
-12%

RETURN ON EQUITY

10 Years:
13%
5 Years:
15%
3 Years:
16%
Last Year:
12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Jun 5

₹ 6.50

Rs.13.0000 per share(650%)Final Dividend

2025

Jun 27

₹ 1.50

Rs.3.0000 per share(150%)Special Dividend

2025

Jun 27

₹ 6.50

Rs.3.0000 per share(150%)Special Dividend

2024

Aug 2

₹ 6.50

Rs.13.0000 per share(650%)Final Dividend

2023

Jul 21

₹ 4.25

Rs.8.5000 per share(425%)Final Dividend

2022

Aug 8

₹ 2.50

Rs.5.0000 per share(250%)Dividend

2021

Aug 9

₹ 2.50

Rs.5.0000 per share(250%)Dividend

2020

Mar 19

Interim Dividend

2018

Aug 13

₹ 1.50

Rs.3.0000 per share(150%)Dividend

2017

Jul 26

₹ 1

Rs.2.0000 per share(100%)Dividend

2016

Sep 12

₹ 1

Rs.2.0000 per share(100%)Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital161161161161161161161161162162
Minority Interest438352332294259276306969688
12,32114,00214,79415,54918,12320,63623,18526,45830,91834,208
4,2514,2414,7873,1611,8971,120563603493792
Trade Payables1,5712,1191,9482,2822,0672,5082,5352,4742,8373,230
2,1271,7971,7401,9762,3301,9512,2582,3372,2373,116
Total Liabilities20,86922,67323,76223,42324,83726,65229,00732,13036,74241,595
9,4909,9499,5479,5599,3949,6229,1019,4949,89512,434
Capital Work in Progress7195123314215713836898641,2131,586
9731,2592,5541,4712,7102,5513,6625,4497,9338,223
3,4854,0453,9654,3784,6695,3505,1565,2385,6426,597
00000004,7715,5065,620
Cash & Bank6249666191,0041,4011,9281,5658758001,307
5,5775,9426,7476,5916,0926,8188,8335,4395,7535,827
Total Assets20,86922,67323,76223,42324,83726,65229,00732,13036,74241,595

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
2,8322,1852,2843,9174,7934,4654,5404,1345,0053,940
Cash from Investing-1,310-854-1,669104-2,387-1,872-2,389-2,988-3,691-2,326
Cash from Financing-1,326-385-349-2,949-1,240-1,600-958-1,200-1,293-1,234
-254223-326224129-146-109-5521380

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
30.9130.9229.1929.2029.1929.2129.2129.2129.21
27.8228.8026.6526.2825.2424.5423.9322.5520.20
24.6623.8727.4127.8828.9729.9730.4431.7034.34
Government0.000.000.000.000.000.000.000.000.00
16.4016.1916.5216.3816.3116.0016.1416.2615.95

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-03
Press Release

2026-09-03 - Cipla Limited has informed the Exchange regarding a press release dated September 03, 2026, titled "Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda® (Pembrolizumab) in the US".

2026-09-03
General Updates

2026-09-03 - Notice to shareholders and creditors in accordance with NCLT Order dated 18th August, 2026 regarding merger of Inzpera Healthsciences Limited with the Company.

2026-09-02
Copy of Newspaper Publication

2026-09-02 - Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares

2026-08-31
Press Release

2026-08-31 - Cipla Limited has informed the Exchange regarding a press release dated August 31, 2026, titled "Cipla and SBP Group sign exclusive licensing agreement for potential best-in-class HER2 bispecific ADC Rolditamig Deuderuxtecan (TQB2102)".

2026-08-28
General Updates

2026-08-28 - Cipla Limited has informed the Exchange about Update on USFDA inspection at InvaGen manufacturing facility in Central Islip, Long Island, NY, USA

2026-08-27
Other Restructuring

2026-08-27 - Cipla Limited has informed the Exchange about Other Restructuring

2026-08-27
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-27 - Cipla Limited has informed the Exchange about Schedule of meet

2026-08-26
ESOP/ESOS/ESPS

2026-08-26 - Cipla Limited has informed the Exchange regarding Allotment of 5281 Shares.

2026-08-25
General Updates

2026-08-25 - Cipla Limited has informed the Exchange about USFDA inspection at Company s manufacturing facility in Pithampur, India

News

Recent coverage and analyst commentary for CIPLA

Loading news…

🤖

AI Stock Analyst

Cipla Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login